title: [The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication].
abstract: OBJECTIVE
  The failure rates of first and second line therapies of Helicobacter pylori (H. pylori) eradication range from 15 to 20%. This study was aimed to evaluate the efficacy and safety of levofloxacin based triple therapy compared with standard triple or quadruple therapy for H. pylori eradication in Korea.
  
  
  METHODS
  We enrolled two hundred and sixty seven patients with presence of H. pylori infection. One hundred and forty-one patients were treated with levofloxacin based triple therapy (LAP; levofloxacin, amoxicillin, proton pump inhibitor; PPI), and 126 patients were treated with standard triple therapy (CAP; clarithromycin, amoxicillin, PPI). We retreated the patients who had failed in H. pylori eradication with standard quadruple second-line therapy (MTPB; metronidazole, tetracycline, PPI, bismuth subcitrate) or levofloxacin based therapy (LAP or LCP; levofloxacin, clarithromycin, PPI).
  
  
  RESULTS
  In first line therapy of H. pylori eradication, the eradication rates of levofloxacin based triple therapy and standard triple therapy were 69.8% and 74.0% respectively (p=0.52). In second-line therapy, the eradication rate of levofloxacin based triple therapy and standard quadruple therapy were 62.5% and 40.0% respectively (p=0.34).
  
  
  CONCLUSIONS
  Levofloxacin based triple therapy is effective as standard regimen to eradicate H. pylori infection and is useful for an alternative rescue therapy as well.
authors.affiliation: Department of Internal Medicine, Bundang CHA Hospital, Pochon CHA University College of Medicine, Seongnam, Korea.
authors.forename: Ji Hyun
authors.initials: JH
authors.lastname: Lee
authors.forename: Sung Pyo
authors.initials: SP
authors.lastname: Hong
authors.forename: Chang Il
authors.initials: CI
authors.lastname: Kwon
authors.forename: Lea Hyun
authors.initials: LH
authors.lastname: Phyun
authors.forename: Byoung Sok
authors.initials: BS
authors.lastname: Lee
authors.forename: Han Ul
authors.initials: HU
authors.lastname: Song
authors.forename: Kwang Hyun
authors.initials: KH
authors.lastname: Ko
authors.forename: Seong Gyu
authors.initials: SG
authors.lastname: Hwang
authors.forename: Pil Won
authors.initials: PW
authors.lastname: Park
authors.forename: Kyu Sung
authors.initials: KS
authors.lastname: Rim
authors.forename: Sehyun
authors.initials: S
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage*
chemical_list: D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D015242:Ofloxacin